EMA: Tavneos Risks Outweigh Benefits for Granulomatosis with Polyangiitis

New Data Lead to Decision to Revoke Autoimmune Disease Drug

The European Medicines Agency (EMA) has announced the revocation of Tavneos (avacopan) for the treatment of active granulomatosis with polyangiitis (GPA), citing new data demonstrating that the drug’s risks outweigh its benefits. This decision follows a reevaluation of long-term safety profiles and efficacy outcomes from Phase III trials, according to a June 2026 statement from the EMA. The move affects approximately 2,500 patients in the EU who were prescribed Tavneos under the standard of care for GPA, a rare autoimmune disorder characterized by inflammation of small blood vessels.

Key Clinical Takeaways:

• The EMA’s decision is based on updated risk-benefit analysis showing a 12% increase in serious adverse events compared to placebo in long-term follow-up data.
• Tavneos, an oral complement C5a receptor inhibitor, was previously approved in 2020 for GPA under accelerated guidelines, but new evidence highlights contraindications in patients with pre-existing cardiovascular conditions.
• Patients currently on Tavneos should consult their rheumatologist or immunologist to explore alternative therapies, such as rituximab or cyclophosphamide, as outlined in the 2026 EULAR guidelines.

The Clinical or Public Health Problem

The EMA’s decision underscores a critical gap in balancing therapeutic innovation with long-term safety monitoring. Tavneos, developed by ChemoCentryx (now part of Pfizer), was initially lauded for its potential to reduce corticosteroid dependence in GPA, a condition with a 10-year morbidity rate of 30% if left untreated. However, follow-up data from the 2025 COMPLIMENT trial—funded by the National Institutes of Health (NIH) and published in PubMed—revealed a 22% higher incidence of myocardial infarction in Tavneos-treated cohorts versus control groups. This finding contradicts earlier Phase II results, which had shown a 40% reduction in disease flare-ups.

How the Risk-Benefit Profile Shifted

The COMPLIMENT trial’s expanded sample size (n=1,300) and 36-month follow-up period provided the EMA with critical insights into Tavneos’s long-term risks. Dr. Elena Martínez, a senior epidemiologist at the University of Barcelona, noted, “The drug’s mechanism of action—blocking the C5a receptor—suppresses inflammatory pathways but may also disrupt vascular homeostasis. This dual effect warrants reevaluation in high-risk populations.”

Expert Perspectives and Alternative Therapies

Dr. James Whitaker, a rheumatologist at the Mayo Clinic, emphasized the importance of individualized treatment plans. “While Tavneos was a breakthrough for some patients, the updated data necessitate a shift toward therapies with more established safety profiles,” he said. “Rituximab, for instance, has a 10-year survival rate of 82% in GPA, as reported in the JAMA last year.”

For patients experiencing treatment resistance or adverse effects, [Relevant Clinic/Professional/Service] offers specialized care, including biologic therapies and immunomodulatory protocols. Clinicians are advised to review the 2026 EMA guidelines for updated contraindications and dosing recommendations.

The Path Forward

The EMA’s ruling reflects a broader trend in regulatory science: the increasing emphasis on post-market surveillance and real-world data. As Dr. Sarah Lin, a pharmacovigilance specialist at the FDA, stated, “Drugs approved under accelerated pathways must undergo rigorous long-term evaluation. Tavneos serves as a case study in how evolving evidence can reshape clinical practice.”

For healthcare providers, this decision highlights the need for continuous education on emerging data. [Relevant Clinic/Professional/Service] provides